JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by YEGIAN, D.
Right arrow Articles by BUDD, V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by YEGIAN, D.
Right arrow Articles by BUDD, V.
Journal of Pharmacology And Experimental Therapeutics, Vol. 84, Issue 4, 318-324, 1945
Copyright © 1945 by American Society for Pharmacology and Experimental Therapeutics

THE PERMEABILITY OF MYCOBACTERIA TO SULFONAMIDES AND SULFONAMIDE-LIKE AGENTS

DIRAN YEGIAN D.V.M.1 and VERA BUDD 1

1 From the New York State Hospital for Incipient Pulmonary Tuberculosis, Ray Brook, New York

Evidence has been obtained by means of a newly described technique that sulfonamides and sulfonamide-like agents enter mycobacterial cells and the possible relation between this fact and the mechanism of bacteriostasis by these agents is discussed.

Sulfonamide-fast mycobacteria produce large amounts of diazotizable material and the development of drug-fastness does not appear to depend upon the change in permeability or binding of the sulfonamide to the bacterial cells.

Mycobacteria killed by various techniques are demonstrated to bind more sulfonamide than do living organisms and the possible significance of this observation is discussed.

Submitted on June 8, 1945






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1945 by the American Society for Pharmacology and Experimental Therapeutics.